Back to Journals » OncoTargets and Therapy » Volume 10

Prognostic value of high IMP3 expression in solid tumors: a meta-analysis

Authors Chen L, Xie Y, Li X, Gu L, Gao Y, Tang L, Chen J, Zhang X

Received 27 November 2016

Accepted for publication 30 March 2017

Published 6 June 2017 Volume 2017:10 Pages 2849—2863

DOI https://doi.org/10.2147/OTT.S128810

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Dr William Cho

Luyao Chen,1,2,* Yongpeng Xie,3,* Xintao Li,1 Liangyou Gu,1 Yu Gao,1 Lu Tang,1 Jianwen Chen,1 Xu Zhang1

1Department of Urology, Chinese PLA General Hospital, Beijing, 2Department of Urology, First Affiliated Hospital of Nanchang University, Nanchang; 3School of Medicine, Nankai University, Tianjin, People’s Republic of China

*These authors contributed equally to this work

Background: Accumulated studies have investigated the prognostic role of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in various cancers, but inconsistent and controversial results were obtained. Therefore, we performed a systematic review and meta-analysis to investigate the potential value of IMP3 in the prognostic prediction of human solid tumors.
Materials and methods: A systematic literature search in the electronic databases PubMed, Embase, Web of Science, and Cochrane library (updated to April 2016) was conducted to identify eligible studies. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for survival outcomes were calculated and gathered using STATA 12.0 software.
Results: A total of 53 studies containing 8,937 patients with solid tumors were included in this meta-analysis. High IMP3 expression was significantly associated with worse overall survival (OS) of solid tumors (HR =2.08, 95% CI: 1.80–2.42, P<0.001). Similar results were observed in cancer-specific survival (CSS), disease-free survival (DFS), recurrence-free survival (RFS), progression-free survival (PFS), and metastasis-free survival (MFS). Further subgroup analysis stratified by tumor type showed that elevated IMP3 expression was associated with poor OS in renal cell carcinoma (RCC), lung cancer, oral cancer, urothelial carcinoma, hepatocellular carcinoma (HCC), colorectal cancer, pancreatic cancer, gastric cancer, and intrahepatic cholangiocarcinoma (ICC).
Conclusion: The current evidence suggests that high IMP3 expression is associated with poor prognosis in most solid tumors. IMP3 is a potential valuable prognostic factor and might serve as a promising biomarker to guide clinical decisions in human solid tumors.

Keywords: IMP3, prognosis, solid tumor, biomarker, meta-analysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]